Haemonetics earnings were $97.3M for the trailing 12 months ending Mar 28, 2026, with -38.1% growth year over year. The latest HAE earnings report on Mar 28, 2026 announced Q1 2026 earnings of -$20.1M, down 145% from last quarter. For the last reported fiscal year 2026 ending Mar 28, 2026, HAE reported annual earnings of $97.3M, with -42% growth.
HAE past earnings growth
How has HAE's earnings growth performed historically?
On HAE's earnings call on Invalid Date, Haemonetics (NYSE: HAE) reported Q1 2026 earnings per share (EPS) of -$0.41, up 135.04% year over year. Total HAE earnings for the quarter were -$20.15 million. In the same quarter last year, Haemonetics's earnings per share (EPS) was $1.17.
As of the last Haemonetics earnings report, Haemonetics is currently profitable. Haemonetics's net profit (also called net income) for the twelve months ending Mar 28, 2026 was $97.31 million, a 41.97% decrease year over year.
What was HAE's earnings growth in the past year?
As of Haemonetics's earnings date in Invalid Date, Haemonetics's earnings has grown -38.14% year over year. This is 45.74 percentage points lower than the US Medical Instruments & Supplies industry earnings growth rate of 7.61%. HAE earnings in the past year totalled $97.31 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.